# Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial

> **NCT04881825** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Zealand Pharma** · enrollment: 129 (estimated)

## Conditions studied

- Short Bowel Syndrome

## Interventions

- **DRUG:** Glepaglutide

## Key facts

- **NCT ID:** NCT04881825
- **Lead sponsor:** Zealand Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-16
- **Primary completion:** 2026-04
- **Final completion:** 2026-04
- **Target enrollment:** 129 (ESTIMATED)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04881825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04881825, "Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04881825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*